Related Experiment Video

Updated: Oct 1, 2026

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Circulating monocyte chemoattractant protein-1 in heart transplant recipients with cardiac allograft vasculopathy

Jean Louis Beaudeux1, Richard Dorent, Maguy Bernard

  • 1Service de Biochimie C, Groupe hospitalier Pitié-Salpêtrière, 83 boulevard de l'hôpital, 75013, Paris, France. jean-louis.beaudeux@psl.ap-hop-paris.fr

Clinical Biochemistry
|April 9, 2002
PubMed

Insights

Serum Monocyte Chemoattractant Protein-1 (MCP-1) levels were higher in heart transplant recipients (HTR) but did not indicate cardiac allograft vasculopathy (CAV). These findings suggest MCP-1 is not a reliable biomarker for CAV post-transplant.

Area of Science:

  • Cardiology
  • Immunology
  • Transplantation

Background:

  • Cardiac allograft vasculopathy (CAV) is a major cause of late graft failure in heart transplant recipients (HTR).
  • Identifying reliable biomarkers for early CAV detection is crucial for improving long-term outcomes.

Purpose of the Study:

  • To investigate the potential of serum Monocyte Chemoattractant Protein-1 (MCP-1) as a diagnostic marker for CAV in HTR.

Main Methods:

  • Serum MCP-1 levels were quantified in 49 HTR, comparing those with and without diagnosed CAV.
  • A control group was included for comparative analysis.

Main Results:

  • HTR demonstrated significantly elevated serum MCP-1 levels compared to healthy controls.
  • No significant difference in serum MCP-1 levels was found between HTR with and without CAV.

Conclusions:

  • Serum MCP-1 does not appear to be a useful biomarker for detecting or monitoring CAV in the context of heart transplantation.
  • Further research may be needed to identify other potential biomarkers for CAV.
Abstract

Related Concept Videos